MedTrace Logo

Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy

NCT02489240 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2016-10-25

No results posted yet for this study

Summary

The investigators planned to research the effect of vitamin D supplementation on the incidence of contrast-induced nephropathy in patients undergoing coronary angiography.

Conditions

  • Contrast-induced Nephropathy

Interventions

DRUG

vitamin D3 tablets

2000 IU vitamin D3 tablets were taken daily for 6 days

DRUG

placebo

2000 IU placebo tablets were taken daily for 6 days

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Principal Investigators

  • Yu Tang Wang, M.D. · PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489240 on ClinicalTrials.gov